Related references
Note: Only part of the references are listed.Will increasing dosing intervals decrease the loss of anti-HPV seropositivity over time?
Leslie R. DeMars et al.
VACCINE (2018)
Global burden of cancers attributable to infections in 2012: a synthetic analysis
Martyn Plummer et al.
LANCET GLOBAL HEALTH (2016)
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials
Aimee R. Kreimer et al.
LANCET ONCOLOGY (2015)
Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study
Katrin Haeussler et al.
VALUE IN HEALTH (2015)
Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe: Potential additional benefit of a nine-valent second generation HPV vaccine compared to first generation HPV vaccines
Susanne Hartwig et al.
PAPILLOMAVIRUS RESEARCH (2015)
Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model
Jorge Alberto Gomez et al.
BMC PUBLIC HEALTH (2014)
Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine
Melanie Drolet et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand
Tony Blakely et al.
VACCINE (2014)
Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands
Tjalke A. Westra et al.
BMC INFECTIOUS DISEASES (2013)
Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: A transmission-dynamic modeling study
Marc Brisson et al.
VACCINE (2013)
Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary
Zoltan Voko et al.
BMC PUBLIC HEALTH (2012)
Global Burden of Human Papillomavirus and Related Diseases
David Forman et al.
VACCINE (2012)
Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model
Deniz Schobert et al.
HEALTH ECONOMICS REVIEW (2012)
The development of instruments to measure the work disability assessment behaviour of insurance physicians
Romy Steenbeek et al.
BMC PUBLIC HEALTH (2011)
Until Which Age Should Women Be Vaccinated Against HPV Infection? Recommendation Based on Cost-effectiveness Analyses
Tjalke A. Westra et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
External Genital Human Papillomavirus Prevalence and Associated Factors Among Heterosexual Men on 5 Continents
Eftyhia Vardas et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Model-Based Analyses to Compare Health and Economic Outcomes of Cancer Control: Inclusion of Disparities
Sue J. Goldie et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Monitoring the safety of quadrivalent human papillomavirus vaccine: Findings from the Vaccine Safety Datalink
Julianne Gee et al.
VACCINE (2011)
Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia
Marko Obradovic et al.
EUROPEAN JOURNAL OF PUBLIC HEALTH (2010)
Cervical Human Papillomavirus Prevalence in 5 Continents: Meta-Analysis of 1 Million Women with Normal Cytological Findings
Laia Bruni et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Cost effectiveness of prophylactic HPV 16/18 vaccination in Finland: results from a modelling exercise
Saku Torvinen et al.
JOURNAL OF MEDICAL ECONOMICS (2010)
Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in the United States
Jane J. Kim et al.
ANNALS OF INTERNAL MEDICINE (2009)
A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females
Andrea M. Anonychuk et al.
BMC PUBLIC HEALTH (2009)
Health and economic impact associated with a quadrivalent HPV vaccine in Italy
F. S. Mennini et al.
GYNECOLOGIC ONCOLOGY (2009)
HPV16/18 vaccination to prevent cervical cancer in The Netherlands: Model-based cost-effectiveness
Veerle M. H. Coupe et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Cost-effectiveness of human papillomavirus vaccination in Belgium: Do not forget about cervical cancer screening
Nancy Thiry et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2009)
Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in the Netherlands
Inge M. C. M. de Kok et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria
Ingrid Zechmeister et al.
VACCINE (2009)
Age-Based Programs for Vaccination against HPV
Elamin H. Elbasha et al.
VALUE IN HEALTH (2009)
The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK
E. J. Dasbach et al.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY (2008)
Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland
Thomas D. Szucs et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France
Christine Bergeron et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2008)
Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination
Jeremy D. Goldhaber-Fiebert et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model
Cara Usher et al.
VACCINE (2008)
Cost-effectiveness of human papillomavirus vaccination in the United States
Harrell W. Chesson et al.
EMERGING INFECTIOUS DISEASES (2008)
Cost-utility analysis of vaccination against HPV in Israel
Gary Michael Ginsberg et al.
VACCINE (2007)
A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program
Shalini Kulasingam et al.
SEXUAL HEALTH (2007)
The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada
Marc Brisson et al.
VACCINE (2007)
Model for assessing human papillomavirus vaccination strategies
Elamin H. Elbasha et al.
EMERGING INFECTIOUS DISEASES (2007)
Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: Mathematical modelling analyses
Ruanne V. Barnabas et al.
PLOS MEDICINE (2006)
Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine
SJ Goldie et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Evaluating human papillomavirus vaccination programs
AV Taira et al.
EMERGING INFECTIOUS DISEASES (2004)
Potential health and economic impact of adding a human papillomavirus vaccine to screening programs
SL Kulasingam et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Share Paper
